Uncertainty in the legal, regulatory, and financial landscape has rendered traditional life sciences acquisitions and partnerships increasingly difficult to execute. Rather than waiting for conditions to reset, acquirers are adopting structures that provide greater flexibility, with the aim of providing acquisition-like control and economics, while deferring and mitigating legal, regulatory, and financial risk. In the partnering context, companies are increasingly adopting structures that combine the deferred economics of an option transaction with the upfront exploitation rights and control of a traditional license. In the M&A context, "license-to-acquire" or "build-to-buy" deals combine elements of an option transaction with a back-end M&A transaction, locking in strategic value without immediate transfer of ownership and control.

The current landscape has complicated M&A underwriting and execution. Acquirers face increased pricing pressure under the U.S. Inflation Reduction Act, increased FDA-EMA divergence, evolving MDR/IVDR standards, and implications of a "most favored nation" pricing regime in the U.S. Emerging technologies such as AI-driven R&D tools are increasingly swept into various export control and data privacy regimes. Acquisitions of certain assets, such as platform technologies, are often subject to heightened control-based antitrust scrutiny, and merger control analysis now routinely extends to negative controls, influence rights, and traditional M&A and licensing structures.

For companies considering M&A, license-to-acquire structures grant purchase rights based on concrete R&D milestones, giving acquirers a pathway to acquisition while deferring ownership and mitigating upfront legal and regulatory risk. This structure also provides certain strategic advantages. For example, acquirers of platform technology can evaluate the technology across their pipelines and shape R&D strategy while potentially deferring control-based antitrust scrutiny. While the scope of rights is narrower than full-fledged licenses, acquirers can also influence IP strategy and obtain freedom to operate while deferring IP ownership until regulatory risk is optimally positioned. A license-to-acquire structure can also preserve the benefits of traditional licensing. For example, exclusivity commitments, step-in rights, and IP reversion mechanisms can ensure an acquirer has meaningful ability to preserve the value of the asset.

When properly structured, license-to-acquire structures allow valuation to crystallize at defined R&D inflection points, provide strategic advantages and flexibility over traditional licensing or acquisition models, and defer ownership and associated risk in an uncertain legal, regulatory, and financial landscape. For today's most valuable pipelines and platforms, this is not a workaround: it is a key component of the deal playbook.